Sana Biotechnology (SANA)
NASDAQ:SANA
Want to see SANA full AI Analyst Report?
Top Page
Sana Biotechnology
(NASDAQ:SANA)
Select Model
Select Model
Rating:43Neutral
Price Target:
$3.00
▼(-14.77% Downside)
Action:Reiterated
Date:05/16/26
The score is held down primarily by weak financial performance (no revenue, sizable losses, and ongoing negative free cash flow) and a bearish technical trend (price below key moving averages with negative MACD). Valuation support is limited by a negative P/E and no dividend, partially offset by corporate events that strengthen cash resources but also highlight ongoing equity-financing/dilution risk.
Positive Factors
Strategic Mayo Clinic investment
A direct equity investment and collaboration with Mayo Clinic ties Sana to a world-class clinical and research partner, aligning incentives on SC451 and islet programs. This strengthens program-specific expertise, clinical development resources, and credibility that can accelerate trials and de-risk commercialization pathways.
Negative Factors
No product revenue; persistent cash burn
Sana remains a pre-revenue developer with substantial, real cash outflows closely tracking accounting losses. Continued negative free cash flow necessitates external funding to sustain pivotal trials and operations, elevating execution risk if future financing windows constrict or clinical setbacks delay milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic Mayo Clinic investment
A direct equity investment and collaboration with Mayo Clinic ties Sana to a world-class clinical and research partner, aligning incentives on SC451 and islet programs. This strengthens program-specific expertise, clinical development resources, and credibility that can accelerate trials and de-risk commercialization pathways.
Read all positive factors
Sana Biotechnology (SANA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$854.36M
Dividend YieldN/A
Average Volume (3M)2.43M
Price to Earnings (P/E)―
Beta (1Y)1.42
Revenue GrowthN/A
EPS Growth-6.15%
CountryUS
Employees194
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.93
Shares Outstanding278,291,600
10 Day Avg. Volume3,390,584
30 Day Avg. Volume2,429,628
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)6.41
Price to Sales (P/S)0.00
P/FCF Ratio-7.12
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-353.78
Enterprise Value/Ebitda-4.70
Forecast
1Y Price Target
$10.17Price Target Upside188.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.63
Revenue Forecast (FY)N/A
Sana Biotechnology Business Overview & Revenue Model
Company Description
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology...
How the Company Makes Money
null...
Sana Biotechnology Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.39M | -12.75M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -180.09M | -178.21M | -255.33M | -268.58M | -256.94M | -345.84M |
| Net Income | -241.99M | -244.17M | -266.76M | -283.25M | -269.48M | -355.93M |
Balance Sheet | ||||||
| Total Assets | 373.59M | 416.89M | 501.02M | 565.30M | 822.72M | 1.13B |
| Cash, Cash Equivalents and Short-Term Investments | 101.14M | 138.38M | 152.50M | 205.19M | 423.96M | 551.00M |
| Total Debt | 75.33M | 78.86M | 94.20M | 104.10M | 108.25M | 110.94M |
| Total Liabilities | 254.35M | 256.01M | 250.52M | 277.79M | 323.40M | 400.90M |
| Stockholders Equity | 119.24M | 160.88M | 250.50M | 287.51M | 499.31M | 728.50M |
Cash Flow | ||||||
| Free Cash Flow | -133.64M | -144.77M | -256.58M | -273.61M | -310.93M | -280.92M |
| Operating Cash Flow | -132.55M | -143.83M | -223.15M | -253.58M | -290.05M | -251.05M |
| Investing Cash Flow | -7.40M | -40.24M | 17.45M | 172.01M | 210.56M | -245.80M |
| Financing Cash Flow | 127.62M | 128.73M | 199.75M | 31.65M | 4.91M | 631.75M |
Sana Biotechnology Technical Analysis
Positive
3.52
Price Trends
3.48
Positive
3.99
Negative
3.97
Negative
Market Momentum
>-0.01
Negative
57.64
Neutral
45.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SANA, the sentiment is Positive. The current price of 3.52 is above the 20-day moving average (MA) of 3.14, above the 50-day MA of 3.48, and below the 200-day MA of 3.97, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 57.64 is Neutral, neither overbought nor oversold. The STOCH value of 45.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SANA.
Sana Biotechnology Risk Analysis
Sana Biotechnology disclosed 82 risk factors in its most recent earnings report. Sana Biotechnology reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sana Biotechnology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.71B | -9.66 | -56.07% | ― | 3.42% | -11.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $4.67B | -9.29 | -30.88% | ― | -89.11% | -37.55% | |
47 Neutral | $827.56M | -68.46 | -28.90% | ― | 68.64% | 50.57% | |
46 Neutral | $256.51M | -2.42 | -677.38% | ― | 7.97% | 59.82% | |
43 Neutral | $854.36M | -4.22 | -141.99% | ― | ― | -6.15% | |
42 Neutral | $529.21M | -3.14 | -188.82% | ― | 4.89% | 24.20% |
* Healthcare Sector Average
SANA
Sana Biotechnology
3.07
1.33
76.44%
GERN
Geron
1.29
0.02
1.57%
EDIT
Editas Medicine
2.62
1.11
73.51%
CRSP
Crispr Therapeutics AG
48.41
9.64
24.86%
TSHA
Taysha Gene Therapies
5.96
3.26
120.74%
PRME
Prime Medicine, Inc.
2.93
1.34
84.28%
Sana Biotechnology Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Sana Biotechnology Raises $69 Million Through Equity Offering
Positive
May 15, 2026
On May 15, 2026, Sana Biotechnology, Inc. reported that it had sold a total of 21,607,878 shares of its common stock under an amended and restated sales agreement with TD Securities (USA) LLC, which acted as the sales agent. The transaction genera...
Executive/Board ChangesRegulatory Filings and Compliance
Sana Biotechnology Rebalances Board Classes With Director Shift
Neutral
Apr 24, 2026
Sana Biotechnology, Inc. announced a governance adjustment on April 22, 2026, to rebalance its Board of Directors in line with its Amended and Restated Certificate of Incorporation. To achieve a more equal distribution across three director classe...
Business Operations and StrategyPrivate Placements and Financing
Sana Biotechnology Secures Strategic Equity Investment from Mayo
Positive
Apr 13, 2026
On April 10, 2026, Sana Biotechnology entered into a stock purchase agreement with Mayo Clinic under which Mayo Clinic will buy 7,507,507 shares at $3.33 per share for roughly $25 million, with an option to purchase an additional 7,507,507 shares ...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Sana Biotechnology Updates ATM Program to Support Development
Positive
Mar 3, 2026
Sana Biotechnology, Inc., based in Seattle and listed on Nasdaq as SANA, operates in the biotechnology industry, focusing on creating and delivering engineered cell and gene therapies. The company’s key platforms include its hypoimmune techn...
Executive/Board Changes
Sana Biotechnology Names Brian Piper as New CFO
Positive
Feb 17, 2026
On February 17, 2026, Sana Biotechnology appointed Brian Piper as Executive Vice President, Chief Financial Officer, Treasurer, and Principal Financial Officer, ending CEO Steve Harr’s interim role as acting principal financial officer. Pipe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.